Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 (TAP) >= 5% status confers therapeutic sensitivity to Capecitabine, Cisplatin, Tislelizumab in patients with Esophageal Squamous Cell Carcinoma.
This statement is based on a regulatory approval from the European Medicines Agency:
Tevimbra, in combination with platinum-based chemotherapy, is indicated for the first-line treatment of adult patients with unresectable, locally advanced or metastatic OSCC whose tumours express PD-L1 with a TAP score >= 5%.